United Therapeutics Corp

Discover how United Therapeutics CEO Martine Rothblatt’s structured 10(b)(5)(1) trading plan reflects confidence in the company’s growth, guiding investors through Q1 earnings and future pipeline prospects.

Executive buying & selling at UTHR shows confidence in growth; a disciplined 10b‑5‑1 plan signals long‑term upside for United Therapeutics investors.

United Therapeutics insider trades show CEO confidence amid buzz; balanced option exercise and sales hint at solid fundamentals and future biotech growth.

Insider activity shows United Therapeutics’ executives are following routine 10(b)(5) plan trades, confirming confidence in the company’s pipeline and valuation.

CEO Martine Rothblatt’s 10b5‑1 option sales signal a planned, long‑term exit at United Therapeutics, reflecting confidence in the company’s growth prospects.

Insider moves at United Therapeutics (UTX) reveal a balanced CFO confidence strategy—buying below market and selling options to manage risk amid biotech volatility.

United Therapeutics’ insider trades reveal a mixed‑signal narrative: CEO Martine Rothblatt’s modest buying amid heavy 10‑b‑5 sales signals confidence but also highlights liquidity pressures that could influence stock volatility.

United Therapeutics CEO Martine Rothblatt’s 10B5‑1 purchase of 9,500 shares signals confidence in the company’s Tyvaso pipeline and strong rally, offering investors insight into insider sentiment amid a 90% year‑to‑date gain.

US insider trades reveal CFO’s deep‑discount purchase of UTX shares, a bullish confidence signal for investors amid a strong biotech pipeline.

Rothblatt’s 10‑b‑5‑1 plan shows UTHR shares bought at $146, while options sell‑offs hit $532‑$545—insider confidence, strategic liquidity, and future upside.